Towards Better Pharmaceutical Provision in Europe-Who Decides the Future?

Area of Science:

• Healthcare innovation
• Pharmaceutical R&D
• European health policy

Background:

• Recent advancements in human health in the European Union include new medicines, vaccines, and treatments.
• Investment in research and development (R&D) is vital for progress in disease prevention and treatment.
• Discussions are ongoing regarding the legislative process to promote new science and technology within the EU regulatory framework.

Purpose of the Study:

• To summarize and rearrange outcomes from a roundtable discussion organized by the European Alliance for Personalised Medicine (EAPM).
• To address challenges in European healthcare and explore how to best promote the benefits of new science and technology.
• To provide a summary under key headings: innovation, unmet medical need, access, security of supply, adapting to progress, and efficiency.

Main Methods:

• Summarization and rearrangement of panel discussions from a roundtable event.
• The outcomes were categorized under specific headings to structure the findings.
• Analysis of challenges and potential solutions within the European healthcare and regulatory framework.

Main Results:

• Identified key areas for improvement in European healthcare: innovation, unmet medical needs, access to medicines, security of supply, adaptation to progress, and efficiency.
• Highlighted the need for a better, holistic vision for the future of pharmaceuticals and health in Europe.
• Emphasized the importance of collaborative efforts among all stakeholders.

Conclusions:

• A call for a unified, holistic vision for the future of pharmaceuticals and health in Europe.
• Stressed the necessity of collaborative action among all stakeholders in the healthcare ecosystem.
• Advocated for viewing medicine delivery as an integral component of a broader healthcare strategy.